Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells

Methotrexate (MTX) is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL). The accumulation of MTX and its active metabolites, methotrexate polyglutamates (MTXPG), in ALL cells is an important determinant of its antileukemic effects. We studied 194 of 356 patients enrolled on St. Jude Total XV protocol for newly diagnosed ALL with the goal of characterizing the intracellular pharmacokinetics of MTXPG in leukemia cells; relating these pharmacokinetics to ALL lineage, ploidy and molecular subtype; and using a folate pathway model to simulate optimal treatment strategies. Serial MTX concentrations were measured in plasma and intracellular MTXPG concentrations were measured in circulating leukemia cells. A pharmacokinetic model was developed which accounted for the plasma disposition of MTX along with the transport and metabolism of MTXPG. In addition, a folate pathway model was adapted to simulate the effects of treatment strategies on the inhibition of de novo purine synthesis (DNPS). The intracellular MTXPG pharmacokinetic model parameters differed significantly by lineage, ploidy, and molecular subtypes of ALL. Folylpolyglutamate synthetase (FPGS) activity was higher in B vs T lineage ALL (p<0.005), MTX influx and FPGS activity were higher in hyperdiploid vs non-hyperdiploid ALL (p<0.03), MTX influx and FPGS activity were lower in the t(12;21) (ETV6-RUNX1) subtype (p<0.05), and the ratio of FPGS to γ-glutamyl hydrolase (GGH) activity was lower in the t(1;19) (TCF3-PBX1) subtype (p<0.03) than other genetic subtypes. In addition, the folate pathway model showed differential inhibition of DNPS relative to MTXPG accumulation, MTX dose, and schedule. This study has provided new insights into the intracellular disposition of MTX in leukemia cells and how it affects treatment efficacy.

[1]  H. Nijhout,et al.  Mathematical Modeling of Folate Metabolism: Predicted Effects of Genetic Polymorphisms on Mechanisms and Biomarkers Relevant to Carcinogenesis , 2008, Cancer Epidemiology Biomarkers & Prevention.

[2]  J. White,et al.  Application of network thermodynamics to the computer modeling of the pharmacology of anticancer agents: a network model for methotrexate action as a comprehensive example. , 1981, Pharmacology & therapeutics.

[3]  Robert J. Bauer,et al.  Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/Pharmacodynamic Data , 2004 .

[4]  Cheng Cheng,et al.  In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile , 2008, PLoS medicine.

[5]  J. Shuster,et al.  Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. , 1990, Blood.

[6]  A. Look,et al.  Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1992, Blood.

[7]  M. Schrappe,et al.  Intermediate Dose Methotrexate Is as Effective as High Dose Methotrexate in Preventing Isolated Testicular Relapse in Childhood Acute Lymphoblastic Leukemia , 1998, Journal of pediatric hematology/oncology.

[8]  M. Relling,et al.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. , 1994, The Journal of clinical investigation.

[9]  H. Nijhout,et al.  In silico experimentation with a model of hepatic mitochondrial folate metabolism , 2006, Theoretical Biology and Medical Modelling.

[10]  M. Relling,et al.  Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. , 1994, Blood.

[11]  Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. , 1990 .

[12]  D C Mikulecky,et al.  Effect of direct suppression of thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site on the interconversion of tetrahydrofolate cofactors to dihydrofolate by antifolates. Influence of degree of dihydrofolate reductase inhibition. , 1991, The Journal of biological chemistry.

[13]  M. Relling,et al.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.

[14]  C. Allegra,et al.  The kinetics of methotrexate polyglutamation in human breast cancer cells. , 1987, Archives of biochemistry and biophysics.

[15]  D C Mikulecky,et al.  Folate-pool interconversions and inhibition of biosynthetic processes after exposure of L1210 leukemia cells to antifolates. Experimental and network thermodynamic analyses of the role of dihydrofolate polyglutamylates in antifolate action in cells. , 1989, The Journal of biological chemistry.

[16]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[17]  Cheng Cheng,et al.  Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. , 2009, Blood.

[18]  Cheng Cheng,et al.  Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. , 2009, JAMA.

[19]  David Z. D'Argenio,et al.  Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis , 2004, Springer US.

[20]  J. Downing,et al.  Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. , 2005, The Journal of clinical investigation.

[21]  Barry Shane,et al.  A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. , 2006, The Journal of nutrition.

[22]  R. Jackson,et al.  Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases. , 1976, Cancer research.

[23]  J. Shuster,et al.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. , 2007, Blood.

[24]  Ching-Hon Pui,et al.  A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia , 2002, Cancer Chemotherapy and Pharmacology.

[25]  S. Raimondi,et al.  Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. , 1999, Blood.

[26]  M. Relling,et al.  De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. , 2002, Blood.

[27]  Yehuda G Assaraf,et al.  Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets. , 2006, Journal of theoretical biology.

[28]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[29]  M. Relling,et al.  Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. , 1997, Molecular pharmacology.

[30]  A. Look,et al.  Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1992, Blood.

[31]  Cornelia M Ulrich,et al.  A Mathematical Model of the Folate Cycle , 2004, Journal of Biological Chemistry.